Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
Roger S McIntyre, Nelson B Rodrigues, Orly Lipsitz, Yena Lee, Danielle S. Cha, Hartej Gill, Leanna M.W. Lui, Mehala Subramaniapillai, Kevin Kratiuk, R. Ho, Rodrigo B. Mansur, Joshua D. Rosenblat
Journal of Affective Disorders March 1, 2021 DOI: 10.1016/j.jad.2021.03.053 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Open-label Peer reviewed |
|---|---|
| Sample size | 64 |
| Population | Adults with treatment-resistant depression receiving intravenous ketamine |
| Intervention | Intravenous ketamine |
| Duration | Acute course of four infusions |
| Topics | Depression Esketamine Ketamine |
| Citations | 10 |
| Key findings | The MARRRS is a valid and sensitive self-report measure for tracking depression symptom changes during rapid-acting antidepressant treatment with ketamine. |
Abstract
Background: Depression severity and efficacy measurement scales employed for rapid-acting treatments (e.g., ketamine) were initially validated in adults receiving conventional monoamine-based antidepressants. The emergence of rapid-acting antidepressants in psychiatry provides the impetus for outcome measures that have been validated as sensitive to change with rapid-acting treatments. Herein, we provide results validating the McIntyre and Rosenblat Rapid Response Scale (MARRRS).
Methods: Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions. The MARRRS is a self-report measure assessing depressive symptoms during the past 72 hours.
Results: Sixty-four patients (Mage = 45.4 ± 13.5) were included. The MARRRS had a high internal consistency across acute infusions as determined by Cronbach's alpha (0.84 to 0.94). There was significant convergent validity between the QIDS-SR-16 and MARRRS total scores across infusions (rs(292) = .87, p < .001); the MARRRS was also sensitive to change (rs(49) = .70, p < .001). Exploratory factor analysis revealed that MARRRS items loaded onto two factors (i.e., dysphoria and psychic anxiety) accounting for 63.4% of the total variance.
Limitations: Heterogenous sample of adults with TRD receiving open-label treatment without placebo comparison.
Conclusion: The MARRRS is a brief validated self-report metric of depression symptom severity that is sensitive to change with the rapid-acting antidepressant ketamine. Measuring outcomes with the MARRRS informs treatment progress and facilitates treatment decisions in persons receiving the rapid-acting antidepressant ketamine. Studies of other rapid-acting antidepressants should incorporate outcome measures that are validated as sensitive to change with rapid-acting antidepressants.